DIRS.INFO The most relevant business & tech news

☆ Earnings will drive the market next week — what we expect from 2 portfolio stocks
▼ + stars: | 2024-05-04 | by ( Zev Fima | ) www.cnbc.com time to read: +10 min

With the Fed, Apple earnings and the jobs report passing with flying colors this week, the runway to more gains looks a lot less cluttered. This past week was chock full of Club earnings: 12 portfolio companies, including Apple , delivered results. Analysts expect Wynn's earnings per share of $1.27 versus 29 cents a year ago when China was not fully back from Covid. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jerome Powell, we're, Jim Cramer, Jim, Apple, Eli Lilly, Estee Lauder, Stanley Black, Decker, Bausch, FactSet, It's, Bob Iger, Iger, Nelson Peltz, We're, Krystal, Berkshire Hathaway, Tyson, Jones Lang, Walt, Ferrari N.V, WK Kellogg, Wynn, Vishay, CRON, MARA, RICK, Ginkgo, Jim Cramer's, David Paul Morris Organizations: Federal Reserve, Apple, GE Healthcare, DuPont, Linde, Bausch Health, Coterra Energy, Club, Disney, Wynn Resorts, CNBC, Revenue, Vegas Sands, Cotai, Boston, Airlines, Krystal Biotech, Alpha Metallurgical Resources, Axsome Therapeutics, Tyson Foods, TSN, Bowlero Corp, CNA Financial Corp, CNA, Jones Lang LaSalle Incorporated, Technologies, Realty Income Corp, Lab, Teradata Corp, Technology, FMC Corporation, FMC, Paymentus Holdings, Shockwave, Vertex Pharmaceuticals, Goodyear Tire & Rubber Company, Simon Property Group, Sterling Construction Company, Apple Hospitality, Boise Cascade Corporation, BellRing Brands, Coty, COTY, Fidelity National Information Services Inc, Vornado Realty, Walt Disney Co, Holdings, Madrigal Pharmaceuticals, Nikola Corporation, BP, Rockwell Automation, MarketAxess Holdings, Jumia Technologies, GEO Group, Builders FirstSource Inc, Duke Energy Corp, WYNN, Rivian Automotive, Arista Networks, Occidental Petroleum Corp, Astera Labs, Bros, Flywire Corporation, B2Gold Corp, Kinross Gold Corp, Virgin Galactic Holdings, iRobot Corp, Electronic Arts Inc, McKesson Corp, ACM Research, Avadel Pharmaceuticals, Toyota Motor Corp, Emerson Electric Co, Perion, Editas, Brink's Company, Sinclair Corporation, New Fortress Energy, Starwood Property Trust, Animal Health, ELAN, Farms, IM Cannabis Corp, Fox Corporation, Formula One, Icahn Enterprises, Teva Pharmaceutical Industries, Arm Holdings plc, ARM, AMC Entertainment Holdings, Trade, AppLovin Corporation, Sciences Corp, SolarEdge Technologies, Roblox Corporation, GigaCloud Technology Inc, Warner Bros ., Properties Trust, Growers, Constellation Energy Group, Cronos, Fiverr, Solar Inc, EPAM Systems, Cedar Fair Entertainment, Digital Holdings, RCI Hospitality Holdings, Akamai Technologies, Semiconductor, Insulet Corp, NuScale Power Corporation, Ginkgo Bioworks Holdings, Bloom Energy Corporation, Construction, AMC Networks, CRH Public Ltd . Company, Jim Cramer's Charitable, Allen, Co . Media, Technology Conference, Bloomberg, Getty Locations: China, Eaton, Amazon, Covid, Macao, Vegas, Sun Valley , Idaho

☆ Friday, May 3, 2024: Jim Cramer says this mega cap still has room to run after its earnings beat
▼ + stars: | 2024-05-03 | by ( ) www.cnbc.com time to read: 1 min

Friday, May 3, 2024: Jim Cramer says this mega cap still has room to run after its earnings beatJim and Jeff discuss their price target raise of this mega cap tech stock. They also talk about the earnings from this energy stock. Finally, they break down the competition for this pharmaceutical stock.

Persons: Jim Cramer, Jim, Jeff

☆ Amgen soars 16% after it talks up a new weight loss drug that could be injected monthly instead of weekly
▼ + stars: | 2024-05-03 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be injected monthly instead of weekly. AdvertisementThe competition is fierce in the GLP-1 weight loss market, with Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjary and Zepbound dominating sales. AdvertisementWhile a monthly weight-loss injected drug may sound appealing to patients, it is likely still far from hitting the market, assuming it passes all of its clinical trials. And even more convenient than a monthly injection of GLP-1 would be a weight loss pill, though Amgen said it ditched development of its oral weight loss drug candidate to instead focus on the development of MariTide.

Persons: —, Amgen, Robert Bradway, Eli Lilly's Mounjary, Bradway, MariTide, James Bradner, Goldman Sachs, it's, hasn't Organizations: Service, Nordisk's Ozempic, Wall Street Locations: America

☆ A top mind at UBS Global Wealth Management explains why investors' meltdown over elevated interest rates is misguided — and shares a 5-part investing blueprint as stocks continue to rise
▼ + stars: | 2024-05-03 | by ( James Faris | ) www.businessinsider.com time to read: +6 min

Less than a month ago, analysts were calling for subdued earnings growth of just 3%. Although higher rates can be a headache, Lefkowitz said earnings growth matters most. Instead of obsessing over when interest rates will fall, Lefkowitz said investors should consider the reasoning behind the Fed's decisions. "If rates are rising and that's leading to more confidence in the earnings growth outlook, then that shouldn't be a headwind to markets," Lefkowitz said. Follow this 5-part investing game planHealthy earnings growth and a resilient economy have strategists at UBS GWM bullish about US stocks.

Persons: Jonathan Golub, weren't, that's, David Lefkowitz, Lefkowitz, —, shouldn't Organizations: UBS Global Wealth Management, UBS, Business, UBS GWM, Bank of America, Federal, Healthcare

☆ Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price cut
▼ + stars: | 2024-05-03 | by ( Shubhangi Goel | ) www.businessinsider.com time to read: +3 min

Read previewDanish drugmaker Novo Nordisk will lower prices of its weight loss drug Wegovy as it plans to raise sales volumes and navigate tough competition. Prices for the blockbuster drug fell in the first quarter. Sales of Wegovy more than doubled in the first quarter year-on-year, to 9.4 billion Danish crowns, or $1.3 billion, according to the company's earnings. They did not specify how much Novo plans to cut Wegovy's prices. AdvertisementThe Danish pharmaceutical maker, which also produces viral weight loss drug Ozempic, reported better-than-expected sales of 65 billion Danish crowns, or $9.4 billion, in the first quarter.

Persons: —, Karsten Munk Knudsen, Knudsen, Lars Fruergaard Jorgensen, Ozempic, Eli Lilly, Wegovy, Bernie Sanders, Goldman Sachs, Oprah Winfrey, Elon Musk, Charles Barkley Organizations: Service, Nordisk, Business Locations: Danish, Novo

☆ Wegovy maker Novo Nordisk down 4%, heads for worst day since October
▼ + stars: | 2024-05-03 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Shares of Danish pharmaceutical giant Novo Nordisk slid 4% on Friday, extending a 2.7% loss on Thursday as analysts pored over the details of the firm's first-quarter results and monitored a potential rival weight loss treatment. The company reported that sales for its blockbuster injectable weight loss treatment Wegovy, more than doubled to 9.38 billion Danish kroner ($1.4 billion). Novo Nordisk, which also makes diabetes treatment Ozempic, said the rise in sales had offset a slight reduction in prices. Analysts expected even higher weight loss drug sales in the quarter, and some noted that Novo Nordisk's 2024 outlook raise for both sales growth and operating profit was due to one-off accounting adjustments. The boom in demand for weight loss treatments saw Novo Nordisk overtake French luxury group LVMH to become Europe's most valuable company last year.

Persons: Karsten Knudsen, Karen Andersen Organizations: Novo Nordisk, Novo, Morningstar Locations: Novo

☆ The market rallied but not our stocks that reported earnings — so we pounced on 2 of them
▼ + stars: | 2024-05-02 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +4 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.

Persons: Jim Cramer, Jerome Powell, doesn't, Stanley Black, Decker, toolmaker Stanley Black, Estee Lauder, Locker, Jim, Jim Cramer's Organizations: CNBC, Linde, Marshalls, TJX Companies, Health, Apple, Coterra, Jim Cramer's Charitable Locations: China

☆ Jim Cramer shares his thoughts on AMD, Johnson & Johnson, CVS Health, Super Micro and Pinterest
▼ + stars: | 2024-05-01 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

CVS Health : Shares tumbled 18% after the company's first-quarter results fell short of Wall Street estimates. "It's just a bad business," Cramer said, noting CVS faces headwinds in both its drugstore and insurance businesses. Super Micro Computer : Shares plunged nearly 18% after the AI server maker's fiscal third-quarter revenue slightly missed estimates. The decline comes despite Super Micro raising its full-year sales guidance. Pinterest : Shares jumped more than 20% after the social media company's first-quarter sales and adjusted earnings topped expectations.

Persons: Jim Cramer's, Jim Cramer, Johnson, Cramer, Pinterest, It's Organizations: CNBC, Club, AMD, CVS, Super Micro

☆ Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
▼ + stars: | 2024-05-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefiting from its broad cost-cutting program and strong sales of its non-Covid products. Pfizer reiterated its previous revenue forecast of $58.5 billion and $61.5 billion, which it first outlined in mid-December. For the first quarter, Pfizer booked net income of $3.12 billion, or 55 cents per share. That compares with net income of $5.54 billion, or 97 cents per share, during the same period a year ago. Paxlovid booked $2 billion in revenue for the quarter, down 50% from the same period a year ago.

Persons: Pfizer's, Paxlovid Organizations: Pfizer, Wednesday, LSEG, Revenue, U.S, Paxlovid Locations: U.S, Seagen, China

☆ Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.
▼ + stars: | 2024-05-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Johnson & Johnson baby powder is displayed in San Anselmo, California, on April 5, 2023. Johnson & Johnson on Wednesday said it will pay $6.5 billion to settle nearly all of the thousands of lawsuits in the U.S. claiming its talc-based products caused ovarian cancer. It will begin a three-month voting period for claimants, in hopes of reaching a consensus on a settlement of all current and future ovarian cancer claims. About 99% of the talc-related lawsuits filed against J&J and its subsidiaries stem from ovarian cancer. The pharmaceutical giant said it has already resolved 95% of mesothelioma lawsuits filed to date.

Persons: Johnson, J Organizations: LTL, J Locations: San Anselmo , California

☆ Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street's expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound. Eli Lilly also expects revenue for the year to come in between $42.4 billion and $43.6 billion, an increase of $2 billion at either end of the range. Shares of Eli Lilly jumped almost 8% in premarket trading Tuesday. With a market cap of about $700 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, LSEG, They're Organizations: Analysts, LSEG Locations: San Diego , California, U.S

☆ Biden administration plans to reclassify marijuana, easing restrictions nationwide
▼ + stars: | 2024-04-30 | by ( Julie Tsirkin | Monica Alba | ) www.cnbc.com time to read: +7 min

"DOJ continues to work on this rule," a Biden administration official said. "No one should be jailed for using or possessing marijuana," the president said during the speech. "Reclassifying marijuana as a Schedule III drug sends the message that marijuana is less addictive and dangerous now than ever before. US President Joe Biden speaks during the White House Correspondents' Association (WHCA) dinner at the Washington Hilton, in Washington, DC, on April 27, 2024. Nearly six in ten Americans say that marijuana should be legal for medical and recreational purposes, according to a Pew Research poll last month.

Persons: John Tlumacki, Biden, Joe Bidens, Tom Williams, Joe Biden, Barack Obama's, Jim Cole, Obama, Cole, Kevin Sabet, Brendan Smialowski, Brad Horrigan Organizations: Delta, Trade, Boston Globe, NBC, Drug, Department of Health, Human Services, DOJ, Biden, Internal Revenue, Justice's, DC Marijuana Justice, CQ, Inc, Getty, State, National Cannabis Roundtable, NBC News, Smart, Marijuana, Obama Administration, White, Correspondents ' Association, Washington Hilton, AFP, Management, CRA, Pew Research, Florida Supreme, Tribune, Service Locations: Wareham, deducting, New York, California, Washington ,, Florida

☆ Tuesday, April 30, 2024: Jim Cramer says this industrial stock will see tailwinds from data centers
▼ + stars: | 2024-04-30 | by ( ) www.cnbc.com time to read: 1 min

Tuesday, April 30, 2024: Jim Cramer says this industrial stock will see tailwinds from data centersJim and Jeff discuss the full-year outlook raise of this pharmaceutical stock. They also talk about this industrial stock ahead of its earnings call. Finally, they discuss the earnings miss for this health care stock.

Persons: Jim Cramer, Jeff

☆ GE Healthcare's disappointing first quarter offers both a lesson and an opportunity
▼ + stars: | 2024-04-30 | by ( Jeff Marks | ) www.cnbc.com time to read: +10 min

GE Healthcare shares sank Tuesday after the company's first-quarter sales and profits fell slightly short of the Wall Street consensus. GE Healthcare Why we own it : GE Healthcare is the global leader in medical imaging, diagnostics, and digital solutions in health care. That's what we have to say about this GE Healthcare quarter. This contributed to some of the softness in the first quarter quarter. The GE Healthcare scanner is called the Revolution CT. Martin Schutt | picture alliance | Getty Images

Persons: didn't, GE Healthcare's, —, it's, Peter Arduini, Jim Cramer's, Jim Cramer, Jim, Martin Schutt Organizations: GE Healthcare, LSEG, General Electric, Philips, Siemens, GE Healthcare YTD, GE, Management, Alzheimer's, CNBC, Getty Locations: China, Covid, Jena , Germany

☆ FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk's blockbuster drugs Ozempic, Saxenda and Victoza. The FTC issued letters to 10 companies, warning them that certain drug patents were improperly listed. Many of the drug patents are for Type 2 diabetes, along with asthma and inhalers for chronic obstructive pulmonary disease, or COPD. Generic drugmakers can only launch cheaper versions of a branded drug if the patents have expired or are successfully challenged in court. The FTC first challenged dozens of branded drug patents last fall, leading three drugmakers to comply and delist their patents with the FDA.

Persons: Novo, Boehringer, Lina Khan, Biden, drugmakers, Joe Biden's Organizations: Federal Trade Commission, FTC, Novo Nordisk, AstraZeneca, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Food and Drug Administration, FDA Locations: U.S

☆ Perimenopause may spike risk of depression, study finds
▼ + stars: | 2024-04-30 | by ( Kristen Rogers | ) edition.cnn.com time to read: +6 min

Now, a new study has quantified the risk of depression during the transition, known as perimenopause — showing that women in this stage are about 40% more likely to experience the mental health condition than premenopausal women. The authors conducted the study — which is a review of seven studies totaling 9,141 women — to provide an estimate for the risk of developing clinical, diagnosed depression or depressive symptoms at different menopausal stages. The authors didn’t find a significant difference in risk of depression for postmenopausal women compared with premenopausal women. Badawy is now an associate graduate mental health worker at the Barnet, Enfield and Haringey Mental Health NHS Trust in London. And doctors should develop and maintain relationships with mental health providers to whom they can refer patients diagnosed with depression.

Persons: ”, Aimee Spector, ” Spector, —, didn’t, Stephanie Faubion, Penny, Bill George, Faubion wasn’t, Yasmeen Badawy, ” Faubion, Faubion, Rebecca Thurston, wasn’t, Thurston, “ Organizations: CNN, Disorders, University College London, Johns Hopkins Medicine, Mayo Clinic’s Center, Women’s Health, Barnet, Haringey Mental Health, Trust, Pittsburgh, University of Pittsburgh, Lifeline Locations: United States, Australia, China, Netherlands, Switzerland, Minnesota, Enfield, Haringey, London

☆ Meet the little people whose bodies may hold a key to longevity
▼ + stars: | 2024-04-30 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +10 min

Sandra TorresTorres has a rare disorder called Laron syndrome that is caused by a genetic mutation. “This is how powerful this mutation seems to be.”What is Laron syndrome? Laron syndrome is a recessive gene, so only those who receive a copy from each parent will be affected. The condition leads to extreme obesity, a trigger for diabetes, heart disease, cancer and other diseases. While technically overweight at 100 pounds (45.4 kilograms), she was in good health, with no signs of diabetes or heart disease.

Persons: Paola Castro Torres, ” Torres, Torres, “, ” Nathaly Paola Castro Torres, Sandra Torres Torres, ”, Valter Longo, Longo, Laron, Jaime Guevara, Aguirre, Guevara, ” Longo, ” Guevara, Andrew Freeman, Freeman, ” Hope, it’s Organizations: CNN, gerontology, University of Southern, of Endocrinology, Laron, Jewish Health Locations: Los Angeles, Quito, Ecuador, University of Southern California, Israel, Yemen, East, United States, Croatia, Ireland, Denver

The US Department of Justice is expected to recommend that marijuana be rescheduled as a Schedule III controlled substance, a classification shared by prescription drugs such as ketamine and Tylenol with codeine. The standard rulemaking process is lengthy, is subject to a public comment period, and could take months to complete. However, rescheduling marijuana will not solve that federal-state conflict, the Congressional Research Service noted in a January 16 brief. States with medical marijuana programs do currently have some federal protections in place via appropriations legislation that restricts the Justice Department from interfering in those programs. The FDA’s scientific and medical evaluation of marijuana did not address products containing plant-derived cannabidiol, commonly known as CBD.

Persons: CNN —, Biden, General Merrick Garland, Joe Biden Organizations: CNN, US Department of Justice, Associated Press, White, Office of Management, US Health, Human Services, Food and Drug, Justice Department, Staff, National Institute on Drug, Delta, National Conference of State Legislatures, Congressional Research Service, CRS Locations: Colorado

☆ Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations
▼ + stars: | 2024-04-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A federal judge in New Jersey on Monday rejected Johnson & Johnson 's and Bristol Myers Squibb 's legal challenges to the Biden administration's Medicare drug-price negotiations, ruling that the program is constitutional. J&J and Bristol Myers Squibb did not immediately respond to requests for comment on the ruling. J&J, Bristol Myers Squibb, Novo Nordisk and Novartis presented their oral arguments before Quraishi during the same hearing in March. That same month, a federal judge in Delaware rejected AstraZeneca's separate lawsuit challenging the negotiations. In Texas, a third federal judge tossed a separate lawsuit in February.

Persons: Johnson, Bristol Myers, Joe Biden's, Zahid Quraishi, Quraishi, Bristol Myers Squibb's, AstraZeneca's Organizations: Bristol, Bristol Myers Squibb, Biden, White, Supreme, Final, of New, Novo Nordisk, Novartis, Chamber of Commerce Locations: New Jersey, U.S, of New Jersey, Delaware, Texas, Ohio

☆ GNC is redesigning stores to draw people taking Ozempic
▼ + stars: | 2024-04-29 | by ( Nathaniel Meyersohn | ) edition.cnn.com time to read: +3 min

The brand hopes a new strategy tailored to people taking GLP-1 drugs for weight loss will help draw customers into stores and grow its business. We can help,” advertises an overhead banner in GNC’s new GLP-1 “support section.”GNC's new GLP-1 support section is available in all 2,300 stores across the United States. JON SIMON/GNCDanish pharmaceutical company Novo Nordisk is reaping huge profits from creating and selling the hit GLP-1 products. JPMorgan researchers estimate that 30 million people may be taking GLP-1 drugs by 2030, or around 9% of the US population. GNC, which filed for bankruptcy in 2020 and closed more than 1,200 stores, is the latest brand to build a strategy around people taking GLP-1s.

Persons: New York CNN — GNC, GNC, ”, JON SIMON, WeightWatchers Organizations: New, New York CNN, Novo Nordisk, Pfizer, Roche, JPMorgan, Equinox Locations: New York, United States, Danish

☆ This bitcoin miner and Nvidia AI cloud partner's stock could go up 50%, Berenberg says
▼ + stars: | 2024-04-29 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Frankfurt-based tech company Northern Data , prominently known for bitcoin mining, has recently transformed its business model into cloud solutions and data center infrastructure. Listed on the Frankfurt Stock Exchange, Northern Data has three core divisions: Peak Mining for bitcoin mining, Taiga Cloud for cloud computing and Ardent Data Centers for data center infrastructure. The company's Taiga Cloud division is certified as an "Elite" partner of Nvidia , making it one of the largest providers of Nvidia-based cloud services in Europe. The investment bank forecasts annual revenues of around 400 million euros and adjusted profits of about 290 million euros from Taiga Cloud from 2026 onward. Northern Data's cloud computing platform is expected to have 20,000 Nvidia AI chips, worth 730 million euros, by the third quarter of 2024, the note said.

Persons: Gerhard Orgonas, Jenna Xu, Aroosh Thillainathan Organizations: Northern Data, Frankfurt Stock Exchange, Data, Mining, Ardent, Healthcare, Northern Bitcoin, Northern, Nvidia, Data's Locations: Frankfurt, Italy, United States, Northern, Pittsburgh, North Dakota, Texas, Europe

☆ U.S. Lags Behind Other Countries in Hepatitis-C Treatment
▼ + stars: | 2024-04-28 | by ( Ted Alcorn | ) www.nytimes.com time to read: 1 min

In the 10 years since the drugmaker Gilead debuted a revolutionary treatment for hepatitis C, a wave of new therapies have been used to cure millions of people around the world of the blood-borne virus. Today, 15 countries, including Egypt, Canada and Australia, are on track to eliminate hepatitis C during this decade, according to the Center for Disease Analysis Foundation, a nonprofit. Each has pursued a dogged national screening and treatment campaign. Spread through the blood including IV drug use, hepatitis C causes liver inflammation, though people may not display symptoms for years. Only a fraction of Americans with the virus are aware of the infection, even as many develop the fatal disease.

Organizations: Center, Disease Analysis Locations: Egypt, Canada, Australia, United States

☆ A top exec at PR giant Edelman lays out its plan to invest in generative AI
▼ + stars: | 2024-04-26 | by ( Lauren Johnson | ) www.businessinsider.com time to read: +4 min

To do so, Edelman recently promoted Brian Buchwald to global chair of product and AI to oversee the firm's AI investments. Buchwald joined Edelman in 2023 and was previously the global head of product, trust data, and technology at the firm. Previously, this tool used small language models and now uses generative AI and large language models, Buchwald said. Using generative AI has increased the tool's ability to predict future trustworthiness with 97% accuracy, he said. More broadly, holding companies have made significant investments into generative AI for content creation that compete with Edelman.

Persons: Edelman, Taco Bell, Brian Buchwald, Buchwald, Weber, Interpublic Group's Weber, Jay Pattisall, Forrester Organizations: eBay, Business, New York Times, Google, Adobe, Edelman, WPP Locations: Talkwaker

☆ Cramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly
▼ + stars: | 2024-04-26 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

It's a week jam-packed with notable events, including earnings from Apple , Amazon and Eli Lilly . He also said to pay attention to Wednesday's Federal Reserve meeting and Friday's employment figures from the Department of Labor. "We have to run such a ridiculous gauntlet next week that I have no idea how it'll play out," he said. Wednesday also brings reports from Wingstop , Carvana and Marriott . Apple will report on Thursday, and Cramer noted there's been a lot of negative sentiment from investors surrounding the company.

Persons: CNBC's Jim Cramer, Eli Lilly, Jensen Huang, Cramer, it's, he'll, Seagen, there's Organizations: Apple, Federal Reserve, Department of Labor, Nvidia, Food and Drug Administration, Starbucks, CVS, Pfizer, Amazon, Walgreens, Marriott, Vision Locations: It's, China, Wingstop, Carvana

☆ Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
▼ + stars: | 2024-04-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Merck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as it posted strong sales of its blockbuster cancer drug Keytruda and vaccine products. The pharmaceutical giant also raised and narrowed its full-year revenue and adjusted earnings forecasts. Merck now expects 2024 sales to come in between $63.1 billion and $64.3 billion, up from previous guidance of $62.7 to $64.2 billion. That outlook includes a one-time charge of roughly 26 cents per share related to Merck's acquisition of Harpoon Therapeutics in January. Merck raked in $15.78 billion in revenue for the quarter, up 9% from the same period a year ago.

Persons: Merck Organizations: Merck, Harpoon Therapeutics, LSEG Locations: Rahway , New Jersey, U.S

Search resuls for: "Pharmaceutical"

25 mentions found